Yes, Eliquis (apixaban) dose can and should be reduced for long-term pulmonary embolism prophylaxis after completing initial treatment.
After at least 6 months of full-dose treatment (5 mg twice daily), reduce to apixaban 2.5 mg twice daily for extended secondary prevention of recurrent PE. This reduced-dose regimen significantly decreases bleeding risk while maintaining equivalent protection against recurrent venous thromboembolism 1.
Initial Treatment Phase (First 6 Months)
For acute PE treatment, the dosing sequence is non-negotiable:
- Days 1-7: Apixaban 10 mg twice daily
- After day 7 through month 6: Apixaban 5 mg twice daily 1
This full-dose regimen during the initial treatment phase is critical for efficacy and cannot be reduced 2.
Extended Treatment Phase (After 6 Months)
For patients requiring long-term anticoagulation beyond 6 months, dose reduction is both appropriate and preferred:
The 2021 CHEST guidelines explicitly recommend reduced-dose DOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily) over full-dose for extended-phase anticoagulation 3. The 2020 American Society of Hematology guidelines similarly suggest either standard-dose or lower-dose DOACs are acceptable options after completing primary treatment 4.
Evidence Supporting Dose Reduction
Multiple high-quality trials demonstrate that reduced-dose apixaban:
- Reduces bleeding by 25-38% compared to full-dose, with significant reductions in clinically relevant bleeding (RR 0.75,95% CI 0.63-0.88) 5, 6
- Maintains equivalent efficacy for preventing recurrent VTE with no significant difference in recurrence rates 5, 7, 8, 6
- Does not increase mortality compared to full-dose regimens 7, 6
The most recent and highest-quality evidence comes from the 2025 API-CAT trial (n=1,766 patients with cancer-associated VTE), which demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose (5 mg twice daily) for preventing recurrent VTE (cumulative incidence 2.1% vs 2.8%, P=0.001 for noninferiority) while significantly reducing clinically relevant bleeding (12.1% vs 15.6%, P=0.03) 7.
Who Should Receive Reduced-Dose Extended Therapy
Reduced-dose apixaban 2.5 mg twice daily is appropriate for:
- Patients with unprovoked PE requiring indefinite anticoagulation 3
- Patients with persistent risk factors (e.g., active cancer, thrombophilia) 2, 7
- Patients at higher bleeding risk who still need VTE prevention 3, 6
Do NOT reduce the dose if:
- Patient is still within the first 6 months of treatment 1
- Patient is taking combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) - these patients should avoid the 2.5 mg dose entirely 1
Critical Dosing Distinctions
A common and dangerous error is confusing atrial fibrillation dosing with VTE dosing. The reduced dose criteria for atrial fibrillation (2.5 mg twice daily if ≥2 of: age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL) do NOT apply to VTE treatment 9, 10, 11. For VTE, the 2.5 mg twice daily dose is used specifically for extended secondary prevention after completing initial therapy, not based on age/weight/renal criteria 1.
The maintenance dose for VTE must be VTE-specific (either 5 mg or 2.5 mg twice daily for extended therapy), not the atrial fibrillation dose 2.
Practical Implementation
Timing of dose reduction:
- Reduce from 5 mg to 2.5 mg twice daily after completing at least 6 months of full-dose therapy 1
- Reassess the need for continued anticoagulation at least annually 3
- Extended anticoagulation does not have a predetermined stop date but should be reevaluated with significant health status changes 3
For patients with cancer-associated PE, the reduced-dose strategy is particularly well-supported, with the 2025 API-CAT trial specifically demonstrating safety and efficacy in this population 7, 8.